| Business

Become a contributor

Bookmark Econotimes

| Business

Samsung Electronics Shares Jump on HBM4 Mass Production Report

Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports

American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns

Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape

Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies

Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning

TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans

Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised

Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks

Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate

Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil

Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing

DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins

Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO

Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal

Washington Post Publisher Will Lewis Steps Down After Layoffs

Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge

©Econometrics LLC . All Rights Reserved.

Vical to Provide Company Update at the 2017 BIO International Convention

Thursday, June 15, 2017 8:05 PM UTC

SAN DIEGO, June 15, 2017 -- Vical Incorporated (Nasdaq:VICL) announced today that the company will provide an overview of its technologies, development programs, and outlook at 4:15 p.m. PT on Wednesday, June 21, at the BIO International Convention (San Diego, June 19 - 22). A webcast of the company’s presentation will be available live and archived through the Events & Presentations page in the Investors section of the Vical website at www.vical.com.

About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, based on its patented DNA delivery technologies and other therapeutic approaches. Additional information on Vical is available at www.vical.com.

Contact:	Andrew Hopkins
(858) 646-1127
Website:  www.vical.com

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Market Data

China Overturns Death Sentence of Canadian Robert Schellenberg, Signaling Thaw in Canada-China Relations

Sydney Braces for Pro-Palestine Protests During Israeli President Isaac Herzog’s Visit

Samsung Electronics Shares Jump on HBM4 Mass Production Report

Ghislaine Maxwell to Invoke Fifth Amendment at House Oversight Committee Deposition

Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible

Trump Congratulates Japan’s First Female Prime Minister Sanae Takaichi After Historic Election Victory

Trump Administration Appeals Court Order to Release Hudson Tunnel Project Funding

Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances

Japan’s Prime Minister Sanae Takaichi Secures Historic Election Win, Shaking Markets and Regional Politics

EconoTimes

Disclaimer: EconoTimes provides references and links to selected blogs and other sources of economic and market information as an educational service to its clients and prospects and does not endorse the opinions or recommendations of the blogs or other sources of information. Clients and prospects are advised to carefully consider the opinions and analysis offered in the blogs or other information sources in the context of the client or prospect's individual analysis and decision making. None of the blogs or other sources of information is to be considered as constituting a track record. Past performance is no guarantee of future results and EconoTimes specifically advises clients and prospects to carefully review all claims and representations made by advisors, bloggers, money managers and system vendors before investing any funds or opening an account with any Brokerage. Any news, opinions, research, data, or other information contained within this website is provided as general market commentary and does not constitute investment or trading advice. EconoTimes expressly disclaims any liability for any lost principal or profits without limitation which may arise directly or indirectly from the use of or reliance on such information. As with all such advisory services, past results are never a guarantee of future results.

Vical to Provide Company Update at the 2017 BIO International Convention

Editor's Picks

Welcome to EconoTimes